Atherosclerosis is a cardiac-based disease where plaque builds up inside the body’s arteries, the blood vessels responsible for carrying oxygen-rich blood to the heart and other organs of the body. Plaque is made up of immune blood cells, known as macrophages, fat, cholesterol, calcium, and other substances found in the blood.
As this plaque hardens it narrows the arteries, limiting the flow of oxygen-rich blood around the body. This, in turn, can lead to serious problems, including heart attack, stroke, or even death.
Nanoparticle eats arterial plaque
Now, a study from researchers led by Michigan State University engineers a nanoparticle capable of eating away, from the inside out, heart attack causing plaques. The team states their nanoparticle reduces and stabilizes plaque, providing a potential treatment for atherosclerosis, a leading cause of death in the United States. The study is published in the journal Nature Nanotechnology.
Previous studies show macrophages have emerged as the main protagonists of atherosclerosis and its complications initiated by an unhealthy lifestyle. Macrophages amass in lesions along the arteries, ingesting lipids, and producing inflammatory mediators known to exacerbate disease.
Pro-phagocytic therapies, which use phagocytosis, an immune mechanism where cells engulf and remove large particles, are currently being explored to stimulate the phagocytic clearance of these lesional macrophages; however, these therapies can damage healthy tissue, which may lead to toxicities such as anemia. The current study develops a pro-phagocytic nanoparticle that delivers a macrophage-specific nanotherapy to clear atherosclerotic plaque safely in mice.
The current study develops a nanoparticle with the ability to eat atherosclerotic plaque using single-walled carbon nanotubes loaded with macrophage-specific nanotherapy. Results show the nanoparticles accumulate in the atherosclerotic plaque, activating phagocytosis, where the macrophages engulf and destroy the plaque in mice safely. Data findings show pro-phagocytic nanoparticles decrease the expression of inflammatory genes linked to cytokine and chemokine pathways in lesional macrophages, a major component of atherosclerotic plaque.
Nanoparticle activates immunity
The group explains their nanoparticle hones in on atherosclerotic plaque due to its high selectivity to monocytes and macrophage immune cells. They go on to add once inside the macrophages in those plaques, it delivers a drug agent to reactivate macrophages, causing them to engulf and eat cellular debris, removing the diseased/dead cells in the plaque core.
The team surmises they have developed a nanoparticle capable of performing phagocytosis on plaques that cause heart attacks. For the future, the researchers state they now plan to test their nanotherapy using large animal models and human tissue tests.
Source: Michigan State University
Don’t miss the latest discoveries from the health innovator community:
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.